{"entity":{"id":"nct07059338","kind":"trial","name":"Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer","aka":["HERBIC"],"tldr":"A phase 2 trial of trastuzumab, cetuximab and fOLFIRI (5-FU, leucovorin, irinotecan) in colorectal cancer, run by Sun Yat-sen University, not yet recruiting.","summary":"Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer is a phase 2, interventional study registered as NCT07059338 by Sun Yat-sen University, with a registry enrolment figure of 34 participants, started 2025-07-11 and due to reach its primary completion in 2027-12-30. Interventions recorded: Trastuzumab +Cetuximab β+Irinotecan. Conditions listed: HER2 Positive; Colorectal Cancer (CRC). Primary outcome: 6-month progression-free-survival rates. Colorectal eligibility wording from the registry: \"* Histologically or cytologically confirmed adenocarcinoma of the colon or rectum with evidence of distant metastasis\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07059338","url":"https://clinicaltrials.gov/study/NCT07059338"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer","her2-amplified-colorectal"],"sections":[],"technologies":["cytotoxic-chemotherapy","monoclonal-antibody","topoisomerase-inhibitors"],"targets":[],"drugs":["trastuzumab","cetuximab","folfiri"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07059338","phase":"2","setting":"Trastuzumab in Combination With Cetuximab and Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer：A Phase II, Open-Label Trial","sponsor":"Sun Yat-sen University","participation":[{"nct":"NCT07059338","source":"https://clinicaltrials.gov/study/NCT07059338","fetchedAt":"2026-10-07T16:55:23.338Z","studySha256":"646fb41d57f937f565d0890d8fb3b5ca8489b4192205956bd8f3b0c80bdda8f2","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2025-07-10","leadSponsor":"Sun Yat-sen University","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":34,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":0,"countries":["China"]}],"started":"2025-07-11","startedType":"estimated","enrolled":34,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07059338/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"her2-amplified-colorectal","kind":"cancer","name":"HER2-amplified colorectal cancer","route":"/cancers/her2-amplified-colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"},{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}